Volume 28, Number 3—March 2022
CME ACTIVITY - Research
Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA
Table 3
Neutralizing antibody titers for enterovirus D68 clades B1, B2 and D, in patients >24 months of age with and without a clinical diagnosis of asthma, Kansas City, Missouri, USA, 2017
| Group | No. patients | Neutralizing antibody, median (range)* |
||
|---|---|---|---|---|
| B1 | B2 | D | ||
| Asthma† | 39 | 9.83 (5.50–10.50) | 9.17 (2.50–10.50) | 9.17 (3.17–10.50) |
| No asthma |
214 |
9.50 (5.83–10.50) |
8.83 (2.50–10.50) |
8.17 (2.50–10.50) |
| Total | 253 | 9.50 (5.50–10.50) | 9.17 (2.50–10.50) | 8.83 (2.50–10.50) |
*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer, http://www.perkinelmer.com); the titers shown are the log2 inverse dilution of the lowest antibody concentration with luminescent activity. Includes seronegative patients. †Asthma as noted by clinician diagnosis in electronic medical record. Because no patients had an asthma diagnosis at <24 mo of age, to balance the age distributions of the nonasthma group with the asthma age group, we excluded nonasthma patients <24 mo of age from this analysis.
1All authors contributed equally to this article.